# Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

> **NCT04142060** · PHASE2 · TERMINATED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04142060
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-01
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Lack of effectiveness
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142060, "Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04142060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*